Brief: Alkermes Announces First Subject Dosed In Phase 1 Study Of of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
11/11/2021 12:02
Nov 11 (Reuters) - Alkermes Plc ALKS.O :
* ALKERMES ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 STUDY OF
ALKS
1140 FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROLOGICAL
DISORDERS
Source text for Eikon: ID:nPn7bpNzMa
Further company coverage: ALKS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Alkermes
See all newsBrief: Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 2 At Sleep 2026
Brief: Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz
Brief: Alkermes Announces Effectiveness Of Mural Oncology Form 10 Registration Statement
Alkermes Plc reports results for the quarter ended in September - Earnings Summary
Brief: Alkermes Q3 Net Income USD 47.8 Million